Предварительные рекомендации по применению вакцины Moderna мРНК-1273 против COVID-19: временное руководство 25 января 2021 г., обновлено 15 июня 2021 г.

Загрузить

English

Français

Pусский

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021 and updated during its extraordinary meeting on 27 May 2021.

These interim recommendations refer to the mRNA-1273 vaccine, manufactured by Moderna. The vaccine is also known as COVID-19 Vaccine Moderna. In the subsequent text the vaccine will be referred to as mRNA-1273.